Agenus Inc (AGEN) revenue by segment
AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$5.97−0.17 (-2.77%)
Close on Nov 20, 2026Market cap $268.77MP/E –Yield –
Doanh thu theo bộ phận của Agenus Inc
Theo bộ phận kinh doanh
Theo sản phẩm hoặc dịch vụ
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalties | $108.59M | $100.98M | $114.57M | $45.29M | $44.36M | – | – | – | – | – | 95.1% | +7.5% |
| Non-Cash Revenue Related to the Sale of Future Royalties | $108.59M | $100.98M | $114.57M | – | – | – | – | – | – | – | 95.1% | +7.5% |
| Pre-Commercial Product Revenue | $4.24M | $0 | $0 | – | – | – | – | – | – | – | 3.7% | – |
| Service Revenue | $1.04M | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | – | – | – | $147.00K | 0.9% | -48.3% |
| Other | $1.04M | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | – | – | – | – | 0.9% | -48.3% |
| Research and Development Revenue | $334.00K | $482.00K | $38.76M | $16.98M | $244.42M | $35.92M | $99.85M | $19.48M | $42.71M | $22.39M | 0.3% | -30.7% |
| Clinical product revenue | $334.00K | $482.00K | $116.00K | $762.00K | $587.00K | – | – | – | – | – | 0.3% | -30.7% |
| Non-Cash Royalty Revenue Related to the Sale of Future Royalties | – | $100.98M | $114.57M | $45.29M | $44.36M | $47.55M | $30.42M | $17.31M | – | – | – | – |
| Research and development services | – | – | $1.44M | $1.68M | $1.48M | $754.00K | $1.71M | $4.15M | $14.62M | $16.87M | – | – |
| Recognition of deferred research and development revenue | – | – | $12.21M | $9.54M | $22.36M | $12.30M | $22.64M | $1.33M | $3.10M | – | – | – |
| License fees and milestones | – | – | $25.00M | $5.00M | $220.00M | $22.86M | – | – | – | – | – | – |
| Recognition of deferred revenue | – | – | – | – | – | – | – | $1.33M | $3.10M | $3.52M | – | – |
| Non-Cash Royalty Revenue Related to the Sale of Future Royalties and Milestones | – | – | – | $45.29M | $44.36M | $47.55M | $30.42M | $17.31M | – | – | – | – |
| Royalty Sales Milestone | – | – | – | $25.25M | – | – | $15.10M | – | – | – | – | – |
| License Fee And Milestones Revenue | – | – | – | – | $220.00M | $22.86M | $75.50M | $14.00M | $24.99M | $2.00M | – | – |
| Other Revenue | – | – | – | – | $184.00K | $91.00K | $4.68M | – | $168.00K | $179.86K | – | – |
| Recognition of Deferred Grant Revenue | – | – | – | – | $184.00K | $91.00K | $1.34M | – | $168.00K | $39.00K | – | – |
| Upfront License Fee | – | – | – | – | – | – | $75.50M | – | – | – | – | – |
| Manufacturing services | – | – | – | – | – | – | $3.34M | – | – | – | – | – |
| License and Collaboration Revenue | – | – | – | – | – | – | – | $23.00M | – | – | – | – |
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $113.16M | $101.46M | $153.34M | $87.51M | $288.96M | $83.55M | $149.36M | $32.78M | $38.88M | $20.33M | 99.1% | +11.5% |
| Rest of World | $1.04M | $2.00M | $2.98M | $10.51M | $6.70M | $4.62M | $690.00K | $4.00M | – | – | 0.9% | -48.3% |
| Europe | – | – | – | – | – | – | $690.00K | $4.00M | $3.99M | $2.24M | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Agenus (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Agenus, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?